Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)

v3.22.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 2,774 $ 8,771 $ 194,133,511 $ (176,902,086) $ 253,734 $ (5,281,180) $ 12,215,524
Beginning balance, shares at Dec. 31, 2020 2,774,394 8,772,198          
Share-based expense 186,206 186,206
Exercise of purchase warrants $ 1 (1)
Exercise of purchase warrants, shares   1,485          
Net loss (2,452,623) (2,452,623)
Ending balance, value at Jun. 30, 2021 $ 2,774 $ 8,772 194,319,716 (179,354,709) 253,734 (5,281,180) 9,949,107
Ending balance, shares at Jun. 30, 2021 2,774,394 8,773,683          
Beginning balance, value at Mar. 31, 2021 $ 2,774 $ 8,772 194,209,794 (178,248,031) 253,734 (5,281,180) 10,945,863
Beginning balance, shares at Mar. 31, 2021 2,774,394 8,773,683          
Share-based expense 109,922 109,922
Net loss (1,106,678) (1,106,678)
Ending balance, value at Jun. 30, 2021 $ 2,774 $ 8,772 194,319,716 (179,354,709) 253,734 (5,281,180) 9,949,107
Ending balance, shares at Jun. 30, 2021 2,774,394 8,773,683          
Beginning balance, value at Dec. 31, 2021 $ 2,774 $ 13,465 205,952,729 (182,547,265) 253,734 (5,281,180) 18,394,257
Beginning balance, shares at Dec. 31, 2021 2,774,394 13,466,603          
Issuance of common stock in connection with purchase of in-process research and development $ 875 804,125 805,000
Issuance of common stock in connection with purchase of in-process research and development, shares   875,000          
Share-based expense 255,465 255,465
Exercise of purchase warrants $ 2 (2)
Exercise of purchase warrants, shares   1,984          
Net loss (4,265,801) (4,265,801)
Ending balance, value at Jun. 30, 2022 $ 2,774 $ 14,342 207,012,317 (186,813,066) 253,734 (5,281,180) 15,188,921
Ending balance, shares at Jun. 30, 2022 2,774,394 14,343,587          
Beginning balance, value at Mar. 31, 2022 $ 2,774 $ 13,467 206,072,322 (184,140,876) 253,734 (5,281,180) 16,920,241
Beginning balance, shares at Mar. 31, 2022 2,774,394 13,468,287          
Issuance of common stock in connection with purchase of in-process research and development $ 875 804,125 805,000
Issuance of common stock in connection with purchase of in-process research and development, shares   875,000          
Share-based expense 135,870 135,870
Exercise of purchase warrants
Exercise of purchase warrants, shares   300          
Net loss (2,672,190) (2,672,190)
Ending balance, value at Jun. 30, 2022 $ 2,774 $ 14,342 $ 207,012,317 $ (186,813,066) $ 253,734 $ (5,281,180) $ 15,188,921
Ending balance, shares at Jun. 30, 2022 2,774,394 14,343,587